Welcome to our dedicated page for PROKIDNEY SEC filings (Ticker: PROK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on PROKIDNEY's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into PROKIDNEY's regulatory disclosures and financial reporting.
PROKIDNEY CORP. reported that Chief Regulatory Officer Darin J. Weber received a grant of 400,000 employee stock options with an exercise price of $0.00 per share. The options vest in substantially equal monthly installments over four years beginning on March 1, 2026.
Girolamo Todd C reported acquisition or exercise transactions in this Form 4 filing.
PROKIDNEY CORP. reported that Chief Legal Officer Todd C. Girolamo received a grant of employee stock options covering 600,000 shares on March 1, 2026. These options vest in substantially equal monthly installments over a four-year period beginning on March 1, 2026, meaning the award is earned gradually rather than all at once.
PROKIDNEY CORP. reported that Chief Executive Officer Bruce Culleton received a grant of employee stock options covering 3,000,000 shares of the company’s stock. These options were awarded as a derivative security with a reported price per share of $0.0000.
According to the filing, the option grant is scheduled to vest in substantially equal monthly installments over a four-year period beginning on March 1, 2026. This means the CEO’s right to exercise the options increases gradually each month over those four years.
Morgan Stanley and Morgan Stanley Investment Management Inc. filed a Schedule 13G reporting beneficial ownership of 8,519,982 shares of ProKidney Corp. Class A common stock, representing 6.0% of the class as of December 31, 2025.
The filing shows no sole voting or dispositive power, with all reported voting and dispositive authority shared between these reporting persons, and certifies that the holdings are maintained in the ordinary course of business without the purpose of changing or influencing control of ProKidney.
ProKidney Corp. filed a current report to share an updated investor presentation that management plans to use in meetings with investors and analysts. The presentation, furnished as Exhibit 99.1 and on the company website, updates the Phase 3 REGEN-006 (PROACT 1) trial plan.
The PROACT 1 study now targets enrollment of approximately 470 subjects. ProKidney continues to expect topline data for the surrogate endpoint (eGFR slope) in the second quarter of 2027 and now anticipates topline data for the confirmatory composite time-to-event endpoint in the second half of 2029, with statistical powering assumptions unchanged.
ProKidney Corp. filed a current report to notify investors that it has updated its investor presentation. Senior management plans to use this updated presentation in meetings with investors and analysts, and it is available on the company’s website as well as attached as Exhibit 99.1. The company states that this material is being furnished under Regulation FD rather than filed, meaning it is not automatically part of other securities law filings unless specifically incorporated by reference. ProKidney also notes that providing this presentation does not represent a determination that the information is material or complete for investment decisions.
ProKidney Corp. furnished a press release announcing its financial results for the quarter ended September 30, 2025. The release is included as Exhibit 99.1 to this report.
The information provided, including Exhibit 99.1, is being furnished and is not deemed “filed” under Section 18 of the Exchange Act, nor incorporated by reference into other filings except as expressly stated.
ProKidney (PROK) reported Q3 2025 results with a net loss including noncontrolling interest of $35.8 million and a net loss available to Class A stockholders of $16.5 million, or $0.12 per share. Revenue was $217,000, reflecting leasing income from tenant agreements.
Operating expenses were $38.8 million, down from $49.0 million a year ago, as research and development totaled $26.8 million and general and administrative was $11.9 million. For the nine months, revenue reached $668,000 and operating loss was $119.6 million.
Liquidity consisted of $95.3 million in cash and cash equivalents and $176.4 million in marketable securities as of September 30, 2025. Net cash used in operating activities was $87.6 million for the nine months. The company sold 1,989,147 Class A shares under its 2025 at-the-market program for $7.1 million during the quarter and, after quarter-end, an additional 5,463,195 shares for $17.1 million in proceeds.
ProKidney completed a domestication to Delaware and related restructuring effective July 1, 2025; management states these transactions did not have a significant impact on the financial statements.
ProKidney Corp. filed Post-Effective Amendment No. 3 to its S-1 on Form S-3, adopting the prior registration after its Delaware domestication under Rule 414. The prospectus now covers up to 169,635,462 shares of Class A common stock for resale by selling securityholders, reflecting updated holder information and a reduction in the number of shares offered since the initial registration.
The company states it will not receive any proceeds from sales by the selling securityholders and will bear registration-related expenses other than underwriting discounts and commissions. No additional securities are being registered in this amendment. ProKidney’s Class A common stock trades on Nasdaq under “PROK.”